Login to Your Account



Hyperion gets diabetes asset with potential $570M Andromeda buy

By Marie Powers
Staff Writer

Thursday, April 24, 2014
Hyperion Therapeutics Inc. broadened its orphan disease pipeline in a big way by inking an agreement to acquire Andromeda Biotech Ltd., an Israel-based subsidiary of Clal Biotechnology Industries Ltd., in a carefully crafted deal that links much of the economics to back-end milestones.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription